The role of interleukin-1 receptor antagonist in the prevention and treatment of disease

Modern Rheumatology

Volumn 13, Issue 1, 2003, Pages 1-6

  Arend, William P ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Cytokines; IL 1 receptor antagonist; Interleukin 1 (IL 1); Rheumatoid arthritis (RA)

Indexed keywords

COMPLEMENTARY DNA; INTERLEUKIN 1; INTERLEUKIN 1 RECEPTOR; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MESSENGER RNA; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PREDNISONE; TUMOR NECROSIS FACTOR ALPHA;

ALLELE; CLINICAL TRIAL; DISEASE PREDISPOSITION; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENDOTHELIUM CELL; EPITHELIUM CELL; GENE THERAPY; HUMAN; INFECTION; INFLAMMATION; INJECTION SITE; LEUKOPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN POLYMORPHISM; PROTEIN SYNTHESIS; RECEPTOR BINDING; RETROVIRUS; REVIEW; RHEUMATOID ARTHRITIS; SKIN MANIFESTATION; TISSUE DISTRIBUTION; VIRAL GENE DELIVERY SYSTEM;

EID: 0043175092     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s101650300000     Document Type: Review

References (42)

1. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996;87:2095-147.
2. Arend WP. Interleukin-1 receptor antagonist. Adv Immunol 1993;54:167-227.
3. Arend WP, Malyak M, Guthridge CJ, Gabay C. Interleukin-1 receptor antagonist: role in biology. Annu Rev Immunol 1998;16:27-55.
4. Arend WP. Interleukin 1 receptor antagonist. A new member of the interleukin 1 family. J Clin Invest 1991;88:1445-51.
5. Gabay C, Smith MF Jr, Eidlen D, Arend WP. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein. J Clin Invest 1997;99:2930-40.
6. Arend WP, Welgus HG, Thompson RC, Eisenberg SP. Biological properties of recombinant human monocyte-derived interleukin 1 receptor antagonist. J Clin Invest 1990;85:1694-7.
7. Fukumoto T, Matsukawa A, Ohkawara S, Takagi K, Yoshinaga M. Administration of neutralizing antibody against rabbit IL-1 receptor antagonist exacerbates lipopolysaccharide-induced arthritis in rabbits. Inflamm Res 1996;45:479-85.
8. Miller LC, Lynch EA, Isa S, Logan JW, Dinarello CA, Steere AC. Balance of synovial fluid IL-1β and IL-1 receptor antagonist and recovery from Lyme arthritis. Lancet 1993;341:146-8.
9. Firestein GS, Boyle DL, Yu C, Paine MM, Whisenand TD, Zvaifler NJ, et al. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum 1994;37:644-52.
10. Gabay C, Marinova-Mutachieva L, Williams RO, Gigley JP, Butler DM, Feldmann M, et al. Increased production of intracellular interleukin-1 receptor antagonist type I in the synovium of mice with collagen-induced arthritis. Arthritis Rheum 2001;44:451-62.
11. Ma Y, Thornton S, Boivin GP, Hirsh D, Hirsch R, Hirsch E. Altered susceptibility to collagen-induced arthritis in transgenic mice with aberrant expression of interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:1798-805.
12. Horai R, Saijo S, Tanioka H, Nakae S, Sudo K, Okahara A, et al. Development of chronic inflammatory arthropathy resembling rheumatoid arthritis in interleukin 1 receptor antagonist-deficient mice. J Exp Med 2000;191:313-20.
13. Nicklin MJH, Hughes DE, Barton JL, Ure JM, Duff GW. Arterial inflammation in mice lacking the interleukin 1 receptor antagonist gene. J Exp Med 2000;191:303-11.
14. Arend WP. The balance between IL-1 and IL-1Ra in disease. Cytokine Growth Factor Rev 2002;13:323-40.
15. Tarlow JK, Blakemore AIF, Lennard A, Solari R, Hughes HN, Steinkasserer A, et al. Polymorphism in human IL-1 receptor antagonist gene intron 2 is caused by variable numbers of an 86-bp tandem repeat. Hum Genet 1993;91:403-4.
16. Perrier S, Coussediere C, Dubost JJ, Albuisson E, Sauvezie B. IL-1 receptor antagonist (IL-1Ra) gene polymorphism in Sjögren's syndrome and rheumatoid arthritis. Clin Immunol Immunopathol 1998;87:309-13.
17. Cantagrei A, Navaux F, Loubet-Lescoulid P, Nourhashemi F, Enault G, Abbal M, et al. Interleukin-1β, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 polymorphisms. Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-100.
18. Barrera P, Faure S, Prud'homme JF, Balsa A, Migliorini P, Chimenti D, et al. European genetic study on rheumatoid arthritis: is there a linkage of the interleukin-1 (IL-1), IL-10 or IL-4 genes to RA? Clin Exp Rheumatol 2001;19:709-14.
19. Genevay S, di Giovine FS, Perneger TV, Silvestri T, Stingelin S, Duff GW, et al. Association of interleukin-4 and interleukin-1β gene variants with Larsen score progression in rheumatoid arthritis. Arthritis Rheum (Arthritis Care Res) 2002;47:303-9.
20. Cvetkovic JT, Wållberg-Jonsson S, Stegmayr B, Rantapää-Dahlqvist S, Lefvert AK. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-α, IL-1β, and IL-1Ra genes. J Rheumatol 2002;29:212-9.
21. Francis SE, Camp NJ, Dewberry RM, Gunn J, Syrris P, Carter ND, et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. Circulation 1999;99:861-6.
22. Francis SE, Camp NJ, Burton AJ, Dewberry RM, Gunn J, Stephens-Lloyd A, et al. Interleukin 1 receptor antagonist gene polymorphism and restenosis after coronary angioplasty. Heart 2001;86:336-40.
23. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscler Thromb Vasc Biol 2000;20:2394-400.
24. Djouadi K, Nedelec B, Tamouza R, Genin E, Ramasawmy R, Charron D, et al. Interleukin 1 gene cluster polymorphisms in multiplex families with spondyloarthropathies. Cytokine 2001;13: 98-103.
25. McGarry F, Neilly J, Anderson N, Sturrock R, Field M. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. Rheumatology 2001;40:1359-64.
26. van der Paarrdt M, Crusius JBA, Garcia-Gonzalez MA, Baudoin P, Kostense PJ, Dijkmans BAC, et al. Interleukin-1β and interleukin-1 receptor antagonist gene polymorphisms in ankylosing spondylitis [abstract]. Arthritis Rheum 2000;43:S264.
27. Moos V, Rudwaleit M, Herzog V, Hlig KH, Seiper J, Müller B. Association of genotypes affecting the expression of interleukin-1β or interleukin-1 receptor antagonist with osteoarthritis. Arthritis Rheum 2000;43:2417-22.
28. Loughlin J, Dowling B, Mustafa Z, Chapman K. Association of the interleukin-1 gene cluster on chromosome 2q13 with knee osteoarthritis. Arthritis Rheum 2002;46:1519-27.
29. Blakemore AIF, Tarlow JK, Cork MJ, Gordon C, Emery P, Duff GW. Interleukin-1 receptor antagonist gene polymorphism as a disease severity factor in systemic lupus erythematosus. Arthritis Rheum 1994;37:1380-5.
30. Suzuki H, Matsui Y, Kashiwagi H. Interleukin-1 receptor antagonist gene polymorphism in Japanese patients with systemic lupus erythematosus. Arthritis Rheum 1997;40:389-90.
31. Tjernström F, Hellmer G, Nived O, Truedsson L, Sturfelt G. Synergistic effect between interleukin-1 receptor antagonist allele (IL1RN*2) and MHC class II (DR17, DQ2) in determining susceptibility to systemic lupus erythematosus. Lupus 1999;8:103-8.
32. Vencovský J, Jarošová K, Růžičková S, Němcová D, Niederlovaá J, Ozen S, et al. Higher frequency of allele 2 of the interleukin-1 receptor antagonist gene in patients with juvenile idiopathic arthritis. Arthritis Rheum 2001;44:2387-91.
33. Rider LG, Artlett CM, Foster CB, Ahmed A, Neeman T, Chanock SJ, et al. Polymorphisms in the IL-1 receptor antagonist gene VNTR are possible risk factors for juvenile idiopathic inflammatory myopathies. Clin Exp Immunol 2000;121:47-52.
34. van Zee KJ, Coyle SM, Calvano SE, Oldenburg HAS, Stiles DM, Pribble J, et al. Influence of IL-1 receptor antagonist blockade on the human response to endotoxemia. J Immunol 1995;154:1499-507.
35. Fisher CJ Jr, Slotman GJ, Opal SM, Peibble JP, Bone RC, Emmanuel G, et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
36. Fisher CJ Jr, Dhainaut J-FA, Opal SM, Pribble JP, Balk RA, Slotman GJ, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results of a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
37. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996;39:1092-101.
38. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant interleukin-1 receptor antagonist. Arthritis Rheum 1998;41: 2196-204.
39. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-9.
40. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. Rheumatology 2001;40:62-9.
41. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in comparison with methotrexate. Arthritis Rheum 2002;46:614-24.
42. Evans CH, Ghivizzani SC, Kang R, Muzzonigro T, Wasko MC, Herndon JH, et al. Gene therapy for rheumatic diseases. Arthritis Rheum 1999;42:1-16.